7.2. Study Product Exposure S tudy product exposure will be summarized by treatment arm and overall for the FAS. N umber of PROSTVAC or placebo PROSTVAC injections administered, number of GM- CSF or placebo GM -CSF injections administered and duration of treatment in days will be summarized using standard descriptive statistics. The number of subjects receiving each scheduled dose will also be summarized using frequency counts and percentages. D uration of tr eatment will be calculated as date of last dose – date of first dose + 1. D osing details will be presented in listings for all subjects 7.3. Post-Vaccination Prostate Cancer Therapy Po st-vaccination prostate cancer therapy will be collected and the number of subjects receiving therapy will be summarized by treatment class and generic trade name, or by treatment class and drug name if generic trade name is missing, using frequency counts and percentages. 8.Efficacy Analysis 8.1.